1. Home
  2. JAGX vs CNSP Comparison

JAGX vs CNSP Comparison

Compare JAGX & CNSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • JAGX
  • CNSP
  • Stock Information
  • Founded
  • JAGX 2013
  • CNSP 2017
  • Country
  • JAGX United States
  • CNSP United States
  • Employees
  • JAGX N/A
  • CNSP N/A
  • Industry
  • JAGX Biotechnology: Pharmaceutical Preparations
  • CNSP Biotechnology: Pharmaceutical Preparations
  • Sector
  • JAGX Health Care
  • CNSP Health Care
  • Exchange
  • JAGX Nasdaq
  • CNSP Nasdaq
  • Market Cap
  • JAGX 3.9M
  • CNSP 4.0M
  • IPO Year
  • JAGX N/A
  • CNSP 2019
  • Fundamental
  • Price
  • JAGX $1.97
  • CNSP $9.20
  • Analyst Decision
  • JAGX Strong Buy
  • CNSP Strong Buy
  • Analyst Count
  • JAGX 1
  • CNSP 1
  • Target Price
  • JAGX $60.00
  • CNSP $20.00
  • AVG Volume (30 Days)
  • JAGX 140.0K
  • CNSP 76.5K
  • Earning Date
  • JAGX 11-12-2025
  • CNSP 11-14-2025
  • Dividend Yield
  • JAGX N/A
  • CNSP N/A
  • EPS Growth
  • JAGX N/A
  • CNSP N/A
  • EPS
  • JAGX N/A
  • CNSP N/A
  • Revenue
  • JAGX $11,810,000.00
  • CNSP N/A
  • Revenue This Year
  • JAGX $22.41
  • CNSP N/A
  • Revenue Next Year
  • JAGX $30.00
  • CNSP N/A
  • P/E Ratio
  • JAGX N/A
  • CNSP N/A
  • Revenue Growth
  • JAGX 15.96
  • CNSP N/A
  • 52 Week Low
  • JAGX $1.57
  • CNSP $4.93
  • 52 Week High
  • JAGX $35.25
  • CNSP $221.94
  • Technical
  • Relative Strength Index (RSI)
  • JAGX 49.42
  • CNSP 69.22
  • Support Level
  • JAGX $1.88
  • CNSP $5.88
  • Resistance Level
  • JAGX $2.16
  • CNSP $6.37
  • Average True Range (ATR)
  • JAGX 0.12
  • CNSP 0.55
  • MACD
  • JAGX 0.06
  • CNSP 0.37
  • Stochastic Oscillator
  • JAGX 67.80
  • CNSP 98.82

About JAGX Jaguar Health Inc.

Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.

About CNSP CNS Pharmaceuticals Inc.

CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.

Share on Social Networks: